



www.genfit.com

## **GENFIT: IMPLEMENTATION OF THE FIFTH INSTALLMENT (€1 M) OF THE RESERVED CONVERTIBLE BOND LOAN AGREEMENT OF €8 M**

- **At GENFIT's initiative, implementation of the fourth of the seven notes redeemable for bonds convertible into shares (BEOCA2012), giving access to a fifth €1 M convertible bond loan.**

**Lille (France), Boston (Massachusetts, United States), February 21, 2013** – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that it has requested the implementation of the fifth installment of €1 M of the €8 M bond loan agreement, convertible into ordinary Company shares, signed on December 20<sup>th</sup>, 2012, in keeping with the 1<sup>st</sup> and 2<sup>nd</sup> resolutions of the Extraordinary Shareholders' Meeting of December 18<sup>th</sup>, 2012.

In keeping with these resolutions and with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd ("the Bondholder"), GENFIT's Management Board decided to authorize the Bondholder to implement the fourth of the seven notes redeemable for bonds convertible into shares ("BEOCA2012"), giving access to 100 new OCA2012-2 bonds, convertible into shares under the same conditions as the first such bonds.

### **About GENFIT:**

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). [www.genfit.com](http://www.genfit.com)

### **Contacts:**

#### **GENFIT**

Jean-François Mouney – CEO & Chairman of the Management Board  
Ph. +333 2016 4000

#### **MILESTONES – Press Relations**

Bruno Arabian  
Ph. +331 7544 8740 / +336 8788 4726 – [barabian@milestones.fr](mailto:barabian@milestones.fr)